The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Increase In Market Value Is Predicted For The Cell-Based Ophthalmic Therapies Market During The 2026–2030 Period?
The cell-based ophthalmic therapies market size has experienced substantial growth in recent years. This market is anticipated to increase from $1.48 billion in 2025 to $1.79 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 20.9%. The historical expansion of this market can be attributed to several factors, including limited treatment alternatives for degenerative eye conditions, an increasing prevalence of retinal and corneal disorders, an expanding aging population, growing awareness of regenerative medicine, and the development of ophthalmic research infrastructure.
The cell-based ophthalmic therapies market size is anticipated to undergo significant expansion in the coming years. It is projected to increase to $3.78 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 20.5%. This growth over the forecast period is driven by advancements in stem cell and gene editing technologies, heightened investment in regenerative ophthalmology, a rise in regulatory approvals for cell-based treatments, increased demand for enduring vision restoration solutions, and the broadening of specialized ophthalmic treatment centers. Noteworthy trends in the upcoming period involve the growing adoption of stem cell and gene therapies for vision restoration, an intensifying focus on regenerative treatments for retinal and corneal disorders, an increase in clinical trials for cell-based ophthalmic therapies, the expansion of personalized and precision ophthalmic treatments, and better long-term outcomes compared to traditional ophthalmic therapies.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27246&type=smp
Which Growth Drivers Are Expected To Support The Cell-Based Ophthalmic Therapies Market Forward?
The growing incidence of ophthalmic disorders is anticipated to stimulate the expansion of the cell-based ophthalmic therapies market in the foreseeable future. Ophthalmic disorders are conditions or diseases that impact the eyes, leading to visual problems or damage to ocular health. These disorders are becoming more common due to the aging population’s increased vulnerability to age-related eye diseases, resulting in vision impairment as life expectancy increases. Cell-based ophthalmic therapies function by repairing or replacing compromised retinal and eye cells to reinstate vision, prevent additional harm, foster regeneration, and improve overall eye function. For instance, in August 2024, according to the Welsh Government, a UK-based government agency, ophthalmology departments in Wales recorded over 35,000 admissions in 2023-24, marking a 5.8% increase from 2022-2023. Thus, the rising prevalence of ophthalmic disorders is a significant driver for the growth of the cell-based ophthalmic therapies market.
What Are The Core Segment Classifications In The Cell-Based Ophthalmic Therapies Market?
The cell-based ophthalmic therapies market covered in this report is segmented –
1) By Therapy Type: Stem Cell Therapy, Gene Therapy, Tissue Engineering
2) By Application: Retinal Disorders, Corneal Disorders, Glaucoma, Other Applications
3) By End-User: Hospitals, Ophthalmic Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Stem Cell Therapy: Embryonic Stem Cell Therapy, Mesenchymal Stem Cell Therapy, Induced Pluripotent Stem Cell Therapy, Retinal Pigment Epithelium Cell Therapy, Limbal Stem Cell Therapy
2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector Based Gene Therapy, In-Vivo Gene Therapy, Ex-Vivo Gene Therapy, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Therapy
3) By Tissue Engineering: Bioengineered Corneal Tissue, Amniotic Membrane Transplantation, Hydrogel-Based Scaffolds, Synthetic Polymer Scaffolds, Decellularized Tissue Constructs
Which Trends Are Affecting The Cell-Based Ophthalmic Therapies Market Framework?
Major companies operating in the cell-based ophthalmic therapies market are focusing on developing advanced treatments, such as allogeneic cell therapy, to address unmet needs in treating corneal endothelial diseases. Allogeneic cell therapy refers to a treatment that utilizes stem cells or other cells donated by a genetically different individual of the same species to repair or replace damaged tissues or treat diseases. For instance, in September 2024, Aurion Biotech, Inc., a US-based clinical-stage biotechnology company, announced the commercial launch of Vyznova (neltependocel) in Japan. It is designed for the treatment of bullous keratopathy, a debilitating condition of the corneal endothelium. Vyznova is believed to be the first approved allogeneic cell therapy specifically targeting corneal endothelial disease, having secured both regulatory and reimbursement approvals in Japan.
Which Organizations Are Involved In The Cell-Based Ophthalmic Therapies Market?
Major companies operating in the cell-based ophthalmic therapies market are F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Astellas Pharma Inc., Sumitomo Pharma Co. Ltd., Healios K.K., Lineage Cell Therapeutics, Pandorum Technologies Pvt. Ltd., Neurotech Pharmaceuticals Inc., Coave Therapeutics SAS, jCyte Inc., Eyestem Research Pvt. Ltd., Opsis Therapeutics, Regenerative Patch Technologies LLC, Emmetrope Ophthalmics LLC, GenSight Biologics S.A., MEDIPOST Co. Ltd., Riken, Luxa Biotechnology Inc.
Access The Complete Cell-Based Ophthalmic Therapies Market Report:
Which Region Stands As The Largest Contributor To The Cell-Based Ophthalmic Therapies Market?
North America was the largest region in the cell-based ophthalmic therapies market in 2025. The regions covered in the cell-based ophthalmic therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Cell-Based Ophthalmic Therapies Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=27246&type=smp
Browse Through More Reports Similar to the Global Cell-Based Ophthalmic Therapies Market 2026, By The Business Research Company
Breathable Membranes Market Report 2026
https://www.thebusinessresearchcompany.com/report/breathable-membranes-global-market-report
Specialty Breathable Membranes Market Report 2026
Vacuum Insulation Market Report 2026
https://www.thebusinessresearchcompany.com/report/vacuum-insulation-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model